Evidence map›Paper›PMID 42662930›Full record

ArticleThe Lancet regional health. Southeast Asia2026

Antimicrobial susceptibility of priority bacterial pathogens from laboratory samples in Timor-Leste: a retrospective analysis of database (2020-2025).

Tessa Oakley, Carolina da Costa Maia, Celita Osorio do Rosario, Messias Soares, Joana Correia Belo, Virginia da Conceição, Névio Sarmento, Lucia Toto, Elfiana Amaral, Domingas da Costa Campos and 12 more

Abstract read
In one paragraph

Article in The Lancet regional health. Southeast Asia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Tessa OakleyMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Carolina da Costa MaiaLaboratório da Saúde do INSP-TL, Dili, Timor-Leste.
Celita Osorio do RosarioLaboratório da Saúde do INSP-TL, Dili, Timor-Leste.
Messias SoaresMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Joana Correia BeloMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Virginia da ConceiçãoMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Névio SarmentoMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Lucia TotoMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Elfiana AmaralMaluk Timor, Dili, Timor-Leste.
Domingas da Costa CamposLaboratório da Saúde do INSP-TL, Dili, Timor-Leste.
Raikos AllanMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Karen ChamplinMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Endang Soares da SilvaPartnership for Human Development, Dili, Timor-Leste.
Ari Jayanti Pereira TilmanLaboratório da Saúde do INSP-TL, Dili, Timor-Leste.
Helio GuterresHospitál Nacionál Guido Valadares, Dili, Timor-Leste.
Lucsendar AlvesMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Anthony Dk DraperMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Benjamin F R DicksonMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Ian MarrMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Jennifer YanMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Heidi Smith-VaughanMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.
Joshua R FrancisMenzies School of Health Research, Charles Darwin University, Dili, Timor-Leste.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Antimicrobial resistance (AMR) is a major global health threat, with the highest burden in low-income and middle-income countries where diagnostic and surveillance capacity are often limited. Over the past decade, Timor-Leste has made substantial progress in strengthening microbial diagnostics and AMR surveillance capacity. We aimed to describe antimicrobial susceptibility patterns and temporal trends among priority bacterial pathogens in Timor-Leste between 2020 and 2025. Methods: We retrospectively analysed antimicrobial susceptibility patterns for WHO priority pathogens isolated from clinical samples processed at the Laboratory of Health, Instituto Nacional de Saúde Pública de Timor-Leste (INSP-TL), between June 2020 and January 2025. WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) priority pathogens were identified using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight mass spectrometry (MALDI-ToF) with automated antimicrobial susceptibility testing (AST) and interpreted using European Committee on AST (EUCAST) breakpoints. Duplicates within 12 months were excluded. Susceptibility proportions, temporal trends, and associations of AMR with sex, age, specimen type, and care were analysed. Findings: Of 4169 isolates, 2170 (52%) were from male and 1943 (47%) from female patients. Among Enterobacterales (1146/4169, 27%) ceftriaxone susceptibility of 65% (410/631) was observed in Interpretation: AMR burden in Timor-Leste is characterised by third-generation cephalosporin resistance, emerging carbapenem-resistant Enterobacterales, and multidrug-resistant Funding: This work was supported by a Fleming Fund Country Grant (UK Aid).

Indexed as

AMR surveillanceAntimicrobial resistanceAntimicrobial susceptibilityCarbapenem resistanceEnterobacteralesESBLExtended-spectrum β-lactamaseGlobal antimicrobial resistance surveillance system (GLASS)Timor-Leste

Identifiers

PMID42662930
PMCPMC13521173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.